Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2016

View Archived Issues

BB-HB-331 demonstrates robust and durable suppression of HBV in vivo

Fudan University discloses sphigomyelin synthase 2 inhibitors

Bayer Schering Pharma patents sGC activators/PDE5 inhibitors

CJ CheilJedang reports FFAR1 agonists for diabetes

Sichuan Haisco Pharmaceutical introduces antineoplastic compounds

Torrent Pharmaceuticals describes MAPK 14 inhibitors

Otsuka Pharmaceutical patents compounds for the treatment of tuberculosis

Immusoft acquires Discovery Genomics

Sound Pharmaceuticals collaborates on phase II study of SPI-1005 for bipolar disorder

Abbott and collaborators launch study to evaluate and diagnose traumatic brain injury

Deflazacort now available through expanded access program for DMD

Partial clinical hold lifted on Medivation's pidilizumab

p53 might be useful to distinguish Langerhans cell hyperplasia from Langerhans cell histiocytosis

Theravance successfully completes single-ascending-dose phase I trial of TD-0714

Alnylam begins phase I/II trial of ALN-GO1 for primary hyperoxaluria type 1

FDA clears in vitro test for identifying carbapenem resistance genes

Nemolizumab demonstrates efficacy in phase II atopic dermatitis trial

Targovax reports 1-year overall survival data on TG-01 in pancreatic cancer

Amal Therapeutics receives Swiss grant to test immunotherapy combination treatments

Interim data from Viamet's phase IIb trial of VT-1161 for recurrent vulvovaginal candidiasis

Evotec achieves preclinical milestone in alliance with Padlock Therapeutics

BAFF expression correlates with severity of mycosis fungoides

Scripps Florida receives funding for obesity and weight control research

SD-101 cream promotes wound healing in patients with epidermolysis bullosa

Genmab achieves new milestone in daratumumab collaboration with Janssen

New Australian trial studies cord blood to treat cerebral palsy

Combioxin initiates phase I study of CAL-02 in severe pneumonia

MEDI-551 receives orphan drug designation for neuromyelitis optica

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...